The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Open accessAbstract
In acute myeloid leukaemia (AML), the cell of origin, nature and biological consequences of initiating lesions, and order of subsequent mutations remain poorly understood, as AML is typically diagnosed without observation of a pre-leukaemic phase. Here, highly purified haematopoietic stem cells (HSCs), progenitor and mature cell fractions from the blood of AML patients were found to contain recurrent DNMT3A mutations (DNMT3A(mut)) at high allele frequency, but without coincident NPM1 mutations (NPM1c) present in AML blasts. DNMT3A(mut)-bearing HSCs showed a multilineage repopulation advantage over non-mutated HSCs in xenografts, establishing their identity as pre-leukaemic HSCs. Pre-leukaemic HSCs were found in remission samples, indicating that they survive chemotherapy. Therefore DNMT3A(mut) arises early in AML evolution, probably in HSCs, leading to a clonally expanded pool of pre-leukaemic HSCs from which AML evolves. Our findings provide a paradigm for the detection and treatment of pre-leukaemic clones before the acquisition of additional genetic lesions engenders greater therapeutic resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies in patients with AML have confirmed the functional importance and clinical significance of preleukemic stem cell populations as the cellular origin of leukemia-initiating cells in human disease27, 48.”
From Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia (2015) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DNMT3A is also recurrently mutated in blood diseases such as acute myeloid leukemia (AML; ref. 9) and myelodysplastic syndromes (MDS; ref. 10) where it functions as an initiating mutation (11).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredIn the citing paper
“In later studies, DNA sequencing of HSCs from AML patients in remission revealed that stem cells with only a single driver mutation were often present, suggesting that pre-malignant clonal hematopoiesis was a generalizable finding in AML 23–25.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Hu, Y., & Smyth, G. K. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.008 · Cited by 2,084
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Cited by
Sorted by citations
Items 401–500 of 1,000
Adipocytes in hematopoiesis and acute leukemia: friends, enemies, or innocent bystanders?
Zinngrebe, J., Debatin, K., & Fischer‐Posovszky, P. (2020) · Leukemia · doi:10.1038/s41375-020-0886-x · Cited by 64
Bhatnagar, B., Eisfeld, A., Nicolet, D., Mrózek, K., Blachly, J. S., Orwick, S. J., Lucas, D. M., Kohlschmidt, J., Blum, W. G., Kolitz, J. E., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14254 · Cited by 54
Chang, Y., You, X., Kong, G., Ranheim, E. A., Wang, J., Du, J., Liu, Y., Zhou, Y., Ryu, M.-J., & Zhang, J. (2015) · Leukemia · doi:10.1038/leu.2015.85 · Cited by 52
Self-citationHematopoietic stem cells are intrinsically protected against MLL-ENL-mediated transformation.
Ugale, A., Norddahl, G., Wahlestedt, M., Säwén, P., Jaako, P., Pronk, C., Soneji, S., Cammenga, J., & Bryder, D. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.036 · Cited by 56
A population genetics perspective on the determinants of intra-tumor heterogeneity
Hu, Z., Sun, R., & Curtis, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.001 · Cited by 54
Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality
Hansen, J. W., Pedersen, D. A., Larsen, L. A., Husby, S., Clemmensen, S. B., Hjelmborg, J., Favero, F., Weischenfeldt, J., Christensen, K., & Grønbæk, K. (2019) · Blood · doi:10.1182/blood.2019001793 · Cited by 53
DNA damage in aging, the stem cell perspective
McNeely, T., Leone, M., Yanai, H., & Beerman, I. (2020) · Human Genetics · doi:10.1007/s00439-019-02047-z · Cited by 52
Bolli, N., Manes, N., McKerrell, T., Chi, J., Park, N., Gundem, G., Quail, M. A., Sathiaseelan, V., Herman, B., Crawley, C. R., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.113381 · Cited by 54
Mesbahi, Y., Trahair, T. N., Lock, R. B., & Connerty, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.807266 · Cited by 52
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia
Gallipoli, P., Giotopoulos, G., & Huntly, B. J. P. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715577614 · Cited by 53
Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia
Corces, M. R., Chang, H. Y., & Majeti, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00263 · Cited by 56
Big Bang Tumor Growth and Clonal EvolutionPreprint
Sun, R., Hu, Z., & Curtis, C. N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028381 · Cited by 61
Wakita, S., Yamaguchi, H., Ueki, T., Usuki, K., Kurosawa, S., Kobayashi, Y., Kawata, E., Tajika, K., Gomi, S., Koizumi, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.288 · Cited by 52
Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia
Wang, M., Yang, C., Zhang, L., & Schaar, D. G. (2017) · Stem Cells International · doi:10.1155/2017/6962379 · Cited by 52
Qian, P., Kumar, B. D., He, X., Nolte, C., Gogol, M., Ahn, Y., Chen, S., Li, Z., Xu, H., Perry, J. M., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.04.012 · Cited by 51
de Haas, V., Ismaila, N., Advani, A. S., Arber, D. A., Dabney, R. S., Patel‐Donnelly, D., Kitlas, E., Pieters, R., Pui, C., Sweet, K. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01468 · Cited by 55
Extracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche
Abdelhamed, S., Butler, J. T., Doron, B., Halse, A., Nemecek, E. R., Wilmarth, P. A., Marks, D. L., Chang, B. H., Horton, T. M., & Kurre, P. (2019) · EMBO Reports · doi:10.15252/embr.201847546 · Cited by 53
The clonal origins of leukemic progression of myelodysplasia
Kim, T., Tyndel, M. S., Kim, H., Ahn, J.-S., Choi, S. H., Park, H., Kim, Y.-K., Yang, D.-H., Lee, J.-J., Jung, S.-H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.17 · Cited by 49
Self-citationForgione, M. O., McClure, B. J., Eadie, L. N., Yeung, D. T. O., & White, D. L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.005 · Cited by 50
Epigenetics: A primer for clinicians
Paluch, B. E., Naqash, A. R., Brumberger, Z. L., Nemeth, M. J., & Griffiths, E. A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.02.002 · Cited by 50
Roles of IDH1/2 and TET2 mutations in myeloid disorders
Inoue, S., Lemonnier, F., & Mak, T. W. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1973-7 · Cited by 52
Bachegowda, L., Morrone, K. A., Winski, S. L., Mantzaris, I., Bartenstein, M., Ramachandra, N., Giricz, O., Sukrithan, V., Nwankwo, G., Shahnaz, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3062 · Cited by 50
Han, L., Jorgensen, J. L., Brooks, C. L., Shi, C., Zhang, Q., Nogueras‐González, G. M., Cavazos, A., Pan, R. A., Mu, H. H., Wang, S. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1904 · Cited by 49
The leukemia strikes back: a review of pathogenesis and treatment of secondary AML
Cheung, E., Perissinotti, A. J., Bixby, D. L., Burke, P. W., Pettit, K. M., Benitez, L. L., Brown, J. M., Scappaticci, G. B., & Marini, B. L. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03606-0 · Cited by 50
Functional profiling of single CRISPR/Cas9-edited human long-term hematopoietic stem cells
Wagenblast, E., Azkanaz, M., Smith, S. A., Shakib, L., McLeod, J. L., Krivdova, G., Araújo, J., Shultz, L. D., Gan, O. I., Dick, J. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12726-0 · Cited by 49
Self-citationShehadi, I. A., Rashdan, H. R. M., & Abdelmonsef, A. H. (2020) · Computational and Mathematical Methods in Medicine · doi:10.1155/2020/8196147 · Cited by 50
Epigenetics in normal and malignant hematopoiesis: An overview and update 2017
Goyama, S., & Kitamura, T. (2017) · Cancer Science · doi:10.1111/cas.13168 · Cited by 53
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia
Shallis, R. M., Weiss, J. J., Deziel, N. C., & Gore, S. D. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100736 · Cited by 51
Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis
Gozdecka, M., Dudek, M., Wen, S., Gu, M., Stopforth, R. J., Rak, J. M., Damaskou, A., Grice, G. L., McLoughlin, M. A., Bond, L., et al. (2025) · Nature · doi:10.1038/s41586-025-08980-6 · Cited by 56
Ageing, immune fitness and cancer
Dolan, M., Libby, K. A., Ringel, A. E., van Galen, P., & McAllister, S. S. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00858-z · Cited by 55
Epigenetic alterations in acute myeloid leukemias
Mehdipour, P., Santoro, F., & Minucci, S. (2014) · FEBS Journal · doi:10.1111/febs.13142 · Cited by 55
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications
Sportoletti, P., Varasano, E., Rossi, R., Mupo, A., Tiacci, E., Vassiliou, G. S., Martelli, M. P., & Falini, B. (2014) · Leukemia · doi:10.1038/leu.2014.257 · Cited by 52
Cellular Mechanisms Underlying Intertumoral Heterogeneity
Sutherland, K. D., & Visvader, J. E. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.07.003 · Cited by 50
Brunetti, L., Battista, V. D., Venanzi, A., Schiavoni, G., Martelli, M. P., Ascani, S., Mecucci, C., Tiacci, E., & Falini, B. (2017) · Leukemia · doi:10.1038/leu.2017.38 · Cited by 51
Biechonski, S., Yassin, M., & Milyavsky, M. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx002 · Cited by 54
Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia
Wang, W., Stiehl, T., Raffel, S., Hoang, V. T., Hoffmann, I., Poisa-Beiro, L., Saeed, B. R., Blume, R., Manta, L., Eckstein, V., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.163584 · Cited by 47
Boileau, M., Shirinian, M., Gayden, T., Harutyunyan, A. S., Chen, C. C. L., Mikael, L. G., Duncan, H. M., Neumann, A. L., Arreba-Tutusaus, P., Jay, N. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10705-z · Cited by 53
Self-citationClonal hematopoiesis, aging, and cardiovascular diseases
Pardali, E., Dimmeler, S., Zeiher, A. M., & Rieger, M. A. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.12.006 · Cited by 50
Convergent epigenetic evolution drives relapse in acute myeloid leukemia
Nuno, K. A., Azizi, A., Köhnke, T., Lareau, C. A., Ediriwickrema, A., Corces, M. R., Satpathy, A. T., & Majeti, R. (2024) · eLife · doi:10.7554/elife.93019 · Cited by 50
Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
Hirsch, P., Tang, R., Abermil, N., Flandrin‐Gresta, P., Moatti, H., Favale, F., Suner, L., Lorre, F., Marzac, C., Fava, F., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.159681 · Cited by 46
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia
Lehmann‐Che, J., Bally, C., Letouzé, É., Berthier, C., Yuan, H., Jollivet, F., Adès, L., Cassinat, B., Hirsch, P., Pigneux, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04384-5 · Cited by 47
Natale, C. D., Manna, S. L., Malfitano, A. M., Somma, S. D., Florio, D., Scognamiglio, P. L., Novellino, E., Netti, P. A., & Marasco, D. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.01.010 · Cited by 47
Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression
Spatari, G., Allegra, A., Carrieri, M., Pioggia, G., & Gangemi, S. (2021) · Cancers · doi:10.3390/cancers13102392 · Cited by 53
Clonal hematopoiesis and its emerging effects on cellular therapies
Bonin, M. V., Jambor, H. K., Teipel, R., Stölzel, F., Thiede, C., Damm, F., Kroschinsky, F., Schetelig, J., Chavakis, T., & Bornhäuser, M. (2021) · Leukemia · doi:10.1038/s41375-021-01337-8 · Cited by 50
TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited
Shin, D.-Y. (2023) · Cancers · doi:10.3390/cancers15194816 · Cited by 46
Lipka, D. B., Wang, Q., Cabezas‐Wallscheid, N., Klimmeck, D., Weichenhan, D., Herrmann, C., Lier, A., Brocks, D., von Paleske, L., Renders, S., et al. (2014) · Cell Cycle · doi:10.4161/15384101.2014.973334 · Cited by 49
Bhola, P. D., Mar, B. G., Lindsley, R. C., Ryan, J. A., Hogdal, L. J., Vo, T. T., DeAngelo, D. J., Galinsky, I. A., Ebert, B. L., & Letai, A. G. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82908 · Cited by 46
RUNX1 cooperates with FLT3-ITD to induce leukemia
Behrens, K., Maul, K., Tekin, N. S., Kriebitzsch, N., Indenbirken, D., Prassolov, V., Müller, U., Serve, H. L., Cammenga, J., & Stocking, C. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160927 · Cited by 48
Hira, V. V. V., Noorden, C. J. F. V., Carraway, H. E., Maciejewski, J. P., & Molenaar, R. J. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.010 · Cited by 48
Parkin, B. L., Londoño-Joshi, A. I., Kang, Q., Tewari, M., Rhim, A. D., & Malek, S. N. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91964 · Cited by 46
The DNMT3A R882H mutant displays altered flanking sequence preferences
Emperle, M., Rajavelu, A., Kunert, S., Arimondo, P. B., Reinhardt, R., Jurkowska, R. Z., & Jeltsch, A. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky168 · Cited by 50
New insights into the biology of acute myeloid leukemia with mutated NPM1
Brunetti, L., Gundry, M. C., & Goodell, M. A. (2019) · International Journal of Hematology · doi:10.1007/s12185-018-02578-7 · Cited by 48
Interactions Between Gut Microbiota and Acute Childhood Leukemia
Wen, Y., Jin, R., & Chen, H. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01300 · Cited by 48
Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells
Wang, Q., Liu, Y., Wang, H., Jiang, P., Qian, W., You, M., Han, Y., Zeng, X., Li, J., Lu, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33410-w · Cited by 47
Joint inference of exclusivity patterns and recurrent trajectories from tumor mutation trees
Luo, X. G., Kuipers, J., & Beerenwinkel, N. (2023) · Nature Communications · doi:10.1038/s41467-023-39400-w · Cited by 41
Borssén, M., Haider, Z., Landfors, M., Norén‐Nyström, U., Schmiegelow, K., Åsberg, A. E., Kanerva, J. A., MADSEN, H. O., Marquart, H. V., Heyman, M. M., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25958 · Cited by 45
Tsai, C. T., & So, C. W. E. (2016) · Oncogene · doi:10.1038/onc.2016.315 · Cited by 49
Grimm, J., Bill, M., Jentzsch, M., Beinicke, S., Häntschel, J., Goldmann, K., Schulz, J. C., Cross, M. A., Franke, G., Behre, G., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0413-0 · Cited by 46
Base editor scanning charts the DNMT3A activity landscape
Lue, N. Z., Garcia, E. M., Ngan, K. C.-H., Lee, C., Doench, J. G., & Liau, B. B. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01167-4 · Cited by 47
Duncavage, E. J., Uy, G. L., Petti, A. A., Miller, C. A., Lee, Y.-S., Tandon, B., Gao, F., Fronick, C. C., O’Laughlin, M. D., Fulton, R. S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745273 · Cited by 44
Stem cell mutations, associated cancer risk, and consequences for regenerative medicine
Derks, L. L. M., & van Boxtel, R. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.09.008 · Cited by 47
Walenda, T., Stiehl, T., Braun, H., Fröbel, J., Ho, A. D., Schroeder, T. A., Goecke, T. W., Rath, B., Germing, U., Marciniak-Czochra, A. K., et al. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003599 · Cited by 44
Clonal hematopoiesis: Pre-cancer PLUS
Silver, A. J., & Jaiswal, S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2018.12.003 · Cited by 46
Rajan, V., Melong, N., Wong, W., King, B. G. C., Tong, R. S., Mahajan, N., Gaston, D., Lund, T. C., Rittenberg, D., Dellaire, G., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.223040 · Cited by 45
Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution
Jiang, Q., Isquith, J. M., Ladel, L., Mark, A., Holm, F., Mason, C. N., He, Y., Mondala, P. K., Oliver, I., Pham, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108670 · Cited by 45
Thoms, J. A. I., Truong, P., Subramanian, S., Knezevic, K., Harvey, G., Huang, Y., Seneviratne, J. A., Carter, D. R., Joshi, S. M., Skhinas, J. N., et al. (2021) · Blood · doi:10.1182/blood.2020009707 · Cited by 42
Peroni, E., Randi, M. L., Rosato, A., & Cagnin, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02841-8 · Cited by 51
Pathogenesis of Myeloproliferative Disorders
Nangalia, J., Grinfeld, J., & Green, A. R. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044454 · Cited by 48
Jiménez, C., Alonso, S., Alcoceba, M., Ordóñez, G. R., García‐Álvarez, M., Prieto-Conde, I., Chillón, C., Balanzategui, A., Corral, R., Marı́n, L., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.72 · Cited by 44
Dillon, L. W., Hayati, S., Roloff, G. W., Tunc, I., Pirooznia, M., Mitrofanova, A., & Hourigan, C. S. (2018) · Haematologica · doi:10.3324/haematol.2018.203133 · Cited by 44
Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
Ewald, L., Dittmann, J., Vogler, M., & Fulda, S. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2156-2 · Cited by 42
Wilhelmson, A. S., & Porse, B. T. (2020) · British Journal of Haematology · doi:10.1111/bjh.16534 · Cited by 45
Emerging role of G9a in cancer stemness and promises as a therapeutic target
Haebe, J. R., Bergin, C. J., Sandouka, T., & Benoit, Y. D. (2021) · Oncogenesis · doi:10.1038/s41389-021-00370-7 · Cited by 43
Chesnais, V., Renneville, A., Toma, A., Lambert, J., Passet, M., Dumont, F., Chevret, S., Lejeune, J., Raimbault, A., Stamatoullas, A., et al. (2015) · Blood · doi:10.1182/blood-2015-04-640128 · Cited by 47
Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia
Tabe, Y., Tafuri, A., Sekihara, K., Yang, H., & Konopleva, M. Y. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1333600 · Cited by 44
Ferret, Y., Boissel, N., Hélevaut, N., Madic, J., Nibourel, O., Marceau‐Renaut, A., Bucci, M., Geffroy, S., Celli‐Lebras, K., Castaigné, S., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.183525 · Cited by 45
Costa, E. M. D., Armaos, G., McInnes, G., Beaudry, A., Moquin‐Beaudry, G., Bertrand-Lehouillier, V., Caron, M., Richer, C., St-Onge, P., Johnson, J. R., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1242-8 · Cited by 45
Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis
Zhang, X., Wang, X., Wang, X. Q. D., Su, J., Putluri, N., Zhou, T., Qu, Y., Jeong, M., Guzman, A. G., Rosas, C., et al. (2020) · Blood · doi:10.1182/blood.2019003330 · Cited by 44
Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia
Panuzzo, C., Signorino, E., Calabrese, C., Ali, M. S., Petiti, J., Bracco, E., & Cilloni, D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030802 · Cited by 43
Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Marando, L., & Huntly, B. J. P. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00918-7 · Cited by 41
Restoring aged stem cell functionality: Current progress and future directions
Spehar, K., Pan, A., & Beerman, I. (2020) · Stem Cells · doi:10.1002/stem.3234 · Cited by 46
Male predominance in AML is associated with specific preleukemic mutations
de-Morgan, A., Meggendorfer, M., Haferlach, C., & Shlush, L. I. (2020) · Leukemia · doi:10.1038/s41375-020-0935-5 · Cited by 45
Self-citationEnasidenib and ivosidenib in AML
Martelli, M. P., Martino, G., Cardinali, V., Falini, B., Martinelli, G., & Cerchione, C. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.07024-x · Cited by 42
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
Forghieri, F., Nasillo, V., Paolini, A., Bettelli, F., Pioli, V., Giusti, D., Gilioli, A., Colasante, C., Acquaviva, G., Riva, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238975 · Cited by 42
Wang, S., Cheng, H., Li, M., Gao, D., Wu, H., Zhang, S., Huang, Y., & Guo, K. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06870-9 · Cited by 43
Loss of Dnmt3b accelerates MLL-AF9 leukemia progression
Zheng, Y., Zhang, H., Wang, Y., Li, X., Lu, P., Dong, F., Pang, Y., Ma, S., Cheng, H., Hao, S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.112 · Cited by 41
Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia
Li, Y., Xu, Q., Lv, N., Wang, L., Zhao, H., Wang, X., Guo, J., Chen, C., Li, Y., & Yu, L. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0409-z · Cited by 42
Towards Quantitative Systems Pharmacology Models of Chemotherapy‐Induced Neutropenia
Craig, M. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12191 · Cited by 39
Disruption of the C/EBPα—miR-182 balance impairs granulocytic differentiation
Wurm, A. A., Zjablovskaja, P., Adamcova, M. K., Gerloff, D., Bräuer-Hartmann, D., Katzerke, C., Hartmann, J.-U., Benoukraf, T., Fricke, S., Hilger, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00032-6 · Cited by 43
A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program
Lin, S., Ptasinska, A., Chen, X., Shrestha, M., Assi, S. A., Chin, P. S., Imperato, M. R., Aronow, B. J., Zhang, J., Weirauch, M. T., et al. (2017) · Blood · doi:10.1182/blood-2016-11-750976 · Cited by 41
Voeltzel, T., Flores-Violante, M., Zylbersztejn, F., Lefort, S., Billandon, M., Jeanpierre, S., Joly, S., Fossard, G., Milenkov, M., Mazurier, F., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1042-7 · Cited by 41
Stem cell donors should be screened for CHIP
Dezern, A. E., & Gondek, L. P. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000394 · Cited by 41
Metastasis: an early event in cancer progression
Hu, Y., Yu, X., Xu, G., & Liu, S. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2279-0 · Cited by 42
Stem-Cell Aging and Pathways to Precancer Evolution
Jamieson, C. H. M., & Weissman, I. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2304431 · Cited by 39
Boucher, J. C., Shrestha, B., Vishwasrao, P., Leick, M. B., Cervantes, E. V., Ghafoor, T., Reid, K. M., Spitler, K., Yu, B., Betts, B. C., et al. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.100751 · Cited by 40
Minimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future Perspectives
Käyser, S., Walter, R. B., Stock, W., & Schlenk, R. F. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0260-7 · Cited by 41
FLT3 inhibitors: clinical potential in acute myeloid leukemia
Hospital, M., Green, A. S., Maciel, T. T., Moura, I. C., Leung, A. Y. H., Bouscary, D., & Tamburini, J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s103790 · Cited by 39
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML
Saenz, D. T., Fiskus, W. C., Manshouri, T., Mill, C. P., Qian, Y., Raina, K., Rajapakshe, K., Coarfa, C., Soldi, R., Bose, P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0334-3 · Cited by 41
Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia
Kościuczuk, E. M., Saleiro, D., & Platanias, L. C. (2016) · Cytokine · doi:10.1016/j.cyto.2016.01.024 · Cited by 40
Giannakopoulou, E., Lehander, M., Culleton, S. V., Yang, W., Li, Y., Kärpänen, T., Yoshizato, T., Rustad, E. H., Nielsen, M. M., Bollineni, R. C., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00642-8 · Cited by 41
Metadata
- Authors
- Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., McLeod, J. L., Doedens, M., Medeiros, J. J. F., Marke, R., Kim, H. J., Lee, K., McPherson, J. D., Hudson, T. J., Pan-Leukemia Gene Panel Consortium, T. H., Brown, A. M. K., Yousif, F., Trinh, Q. M., Stein, L. D., Minden, M. D., Wang, J. C. Y., & Dick, J. E.
- Affiliations
- University Health Network (CA)
- Chonnam National University (KR)
- Ontario Institute for Cancer Research (CA)
- Corresponding author
- Dick, John E.
- ORCID
- Venue
- Nature
- Published
- 2014-02-12
- Volume
- 506
- Issue
- 7488
- Pages
- 328-333
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4991939
- OpenAlex
- W2076031927
- Cited by
- 1,443
- References
- 53
- Citations by year
- 2026: 50 · 2025: 48 · 2024: 75 · 2023: 95 · 2022: 94 · 2021: 110 · 2020: 136 · 2019: 131 · 2018: 139 · 2017: 160 · 2016: 153 · 2015: 159 · 2014: 88
- FWCI
- 132.63
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-04-16)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Hospital for Sick Children
- Canadian Institutes of Health Research (105367_1)
- National Cancer Institute (R21CA152613)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, DNMT3A mutation, NPM1 mutation, clonal evolution, treatment resistance, relapse, clonal expansion, chemotherapy remission, tumor heterogeneity, xenografts, mutation order, hematopoiesis
- MeSH terms
- DNA Methyltransferase 3A, Nucleophosmin, Animals, Cell Differentiation, Cell Division, Clone Cells, DNA (Cytosine-5-)-Methyltransferases, Female, Hematopoiesis, Hematopoietic Stem Cells, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasm Transplantation, Nuclear Proteins, Remission Induction, T-Lymphocytes, Neoplastic Stem Cells, Leukemia, Myeloid, Acute, Mice, SCID, Mice, Inbred NOD, Drug Resistance, Neoplasm, Cell Lineage, Mice, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
